The SH3GLB2 antibody targets the SH3 domain-containing GRB2-like protein B2 (SH3GLB2), a member of the endophilin B family involved in membrane remodeling, vesicle trafficking, and apoptosis. SH3GLB2. also known as endophilin B2 or Bax-interacting factor 1 (Bif-1), plays critical roles in regulating mitochondrial morphology, autophagy, and apoptosis by interacting with proteins like Bax and Beclin-1. It contains a Bin-Amphiphysin-Rvs (BAR) domain, which facilitates membrane curvature sensing, and an SH3 domain that mediates protein-protein interactions. SH3GLB2 is implicated in pathological processes, including cancer progression, neurodegeneration, and metabolic disorders, where its dysregulation may influence tumor suppression, cell survival, or stress responses.
Antibodies against SH3GLB2 are widely used in research to study its expression, localization, and function via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). They are essential tools for investigating SH3GLB2's role in mitochondrial dynamics, autophagy induction, and apoptotic signaling pathways. Validated antibodies typically demonstrate specificity through knockout (KO) controls and cross-reactivity with orthologs in common model organisms (e.g., human, mouse, rat). Researchers utilize these antibodies to explore SH3GLB2's involvement in diseases such as cancer, where it may act as a tumor suppressor, or in neurodegenerative conditions linked to impaired autophagy.